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New biocompatible hydroxy double salts and their drug delivery
properties
A. Y. A. Kaassis,a M. Weib and G. R. Williamsa*
Two biocompatible hydroxy double salts (HDSs) were synthesised
for the first time and loaded with active pharmaceutical
ingredients. Drug release was studied from these intercalates, and
sustained release observed. The HDS-drug composites were further
formulated into tablets which were found to comply with
pharmacopeia requirements for delayed release dosage forms.
HDSs are functionally and structurally similar to the widely
explored layered double hydroxide (LDH) materials. These
contain positive mixed metal hydroxide layers with charge
balancing anions located between the layers. LDHs typically
contain a mixture of divalent and trivalent metal ions. 1–3 The
generic formula of an HDS is [(M2+2-xMe2+x)(OH)4-y]Xn-y/n·zH2O, in
which M2+ and Me2+ correspond to divalent metals ions such as
Cu2+, Co2+, Ni2+, or Zn2+ and Xn- is an exchangeable interlayer
anion.4,5 An example of an HDS is the zinc basic salt (ZBS)
[Zn5(OH)8](NO3)2·2H2O.6–8 This comprise layers of edge-sharing
M(OH)6 octahedra with one third of the octahedral sites vacant
and additional Zn2+ cations situated above and below the layer
in tetrahedral sites. HDSs are generally stable and inert, and
have been employed as biomolecule reservoirs or advanced
green materials.9 They can also be used as antimicrobial
agents,10 antifungal agents,10 in water treatment,11 as
anticorrosion agents12 and in photocatalysis.13
LDHs have been widely explored as drug delivery systems, 14–
16 but HDSs have received much less attention in this regard
with only a handful of reports in the literature. 17–20 The results
that have been obtained with HDSs indicate that in general they
release intercalated active pharmaceutical ingredients (APIs) in
a more sustained manner than LDHs do. 21,22 However, there
remain concerns regarding the accumulation of inorganic
materials in the body upon repeated applications. 23 Hence,
HDSs might be problematic if used in significant quantities to
deliver APIs, should they break down during gastrointestinal
(GI) passage. This is because they commonly contain toxic ions
such as Cu2+ or Ni2+ and it is well known that free metals can be
absorbed during their passage through the GI tract. 24 Zinc is an
essential trace element in humans, so the ZBS system is less
toxic than other HDSs. The LD50 for Zn chloride is around 350
mg/kg in rats when ingested orally. Thus, the ZBS would be safe
if used in small amounts to deliver APIs, but could become toxic
when higher amounts are used.25–27. In order to ameliorate this
issue, here we report two new highly biocompatible HDSs
constructed using Zn, Mg and Fe (the oral LD 50 for MgCl2 and
FeCl2 in rats are 2800 and 895 mg/kg, respectively). We further
describe the incorporation of several APIs into their interlayer
spaces, and the formulation of the resultant HDS-drug
composites into tablets.
New HDSs made from the biocompatible metal ions Fe 2+,
Zn2+, and Mg2+ were prepared (as detailed in the ESI) using FeCl 2,
MgCl2 and ZnO as starting materials. HDSs were generated with
mixtures of Fe/Zn, Mg/Zn, and Zn alone. These are henceforth
denoted MZn-Cl (M = Mg, Fe) or Zn-Cl. The new materials were
first thoroughly characterised to ensure HDS preparation was
successful. FeZn-Cl (Fig. S1, ESI) has a dark green colour. This
implies that the Fe2+ has not been oxidised to Fe3+, and remains
in the divalent oxidation state. Both MgZn-Cl and FeZn-Cl
consist largely of hexagonal platelets (Fig. 1), in good agreement
with the literature on HDSs.28,29 The particle sizes were around
400 nm and positive zeta potentials were observed in water, as
expected for an HDS structure (see Table S3, ESI).
X-ray diffraction (XRD) patterns (Fig. 2) show that MgZn-Cl
and FeZn-Cl are indeed HDSs. Their patterns are very similar to
that of Zn-Cl, showing both strong basal reflections (consistent
with a layered structure) and a number of non-basal reflections
(as a result of the ordered arrangement of ions in the layers).
The MgZn-Cl and FeZn-Cl materials have slightly higher
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interlayer spacings (8.1 and 7.8 Å respectively) than the Zn-Cl
reference material, but can be indexed on very similar unit cells
(full indexing is given in Tables S4 and S5, ESI).
Fig. 1. Scanning electron microscopy images of (a) MgZn-Cl and (b) FeZn-Cl.
Fig. 2. XRD patterns of (a) FeZn-Cl; (b) MgZn-Cl; and, (c) Zn-Cl.
The chemical formulae of the new materials were calculated
with the aid of energy dispersive X-ray (EDX) spectroscopy and
thermogravimetric analysis (TGA) data. EDX analysis (Fig. S2,
ESI) reveals the existence of a mixture of divalent metals (Fe/Zn
and Mg/Zn) in the samples. From the metal ratios, the formulae
of the new HDSs can be calculated as Mg 2.1Zn2.9(OH)8Cl2·yH2O
and Fe2.4Zn2.6(OH)8Cl2·yH2O. In order to protect the Fe2+ from
oxidation, KI was used during the synthesis of FeZn-Cl. The EDX
data show that there is no KI present as an impurity in the FeZn-
Cl product, since no peaks corresponding to either of these
elements can be seen in the EDX spectrum.
Thermogravimetric analysis (TGA) traces are given in Fig. S3.
Mass loss below 400 °C goes through two or three stages, which
is common for LDH and HDS materials. 30–32 For FeZn-Cl, the
initial mass loss of 6.64 % is complete by 160 °C and corresponds
to the loss of two water molecules per formula unit (calcd. mass
loss 6.59 %). With MgZn-Cl, the water mass loss of 12.24 % that
commences below 100 °C and finishes at ca. 200 °C corresponds
to a value of y = 3.4 (calcd. mass loss 12.04 %).
The IR spectra of MgZn-Cl, FeZn-Cl and Zn-Cl (Fig. S4, ESI) all
look similar. MgZn-Cl and FeZn-Cl show broad peaks around
3450 cm-1, which correspond to stretches of the OH groups in
the layers and of interlayer water. In addition, a band around
1635 cm-1 is assigned to the δ-bend of water molecules in the 
interlayer. The M–O and O–M–O (M = Mg, Fe and Zn) vibrations
appear at ca. 700 cm-1,33 while peaks around 1030 and 900 cm -
1 correspond to the bending of OH groups attached to divalent
metal ions.
X-ray photoelectron (XPS) spectra were obtained on the
FeZn-Cl HDS (Fig. S5) to investigate the oxidation state of Fe in
the system. The data show that Fe overwhelmingly exists in the
Fe2+ oxidation state (Table S6), with possibly a small amount of
oxidation having taken place. The Fe 2+ ions are believed to
occupy both octahedral and tetrahedral positions. The Mg 2p
XPS spectrum (Fig. S5 and Table tabS7) also demonstrates that
Mg atoms are also likely occupy both octahedral and
tetrahedral sites in the MgZn-Cl HDS. A schematic of the HDS
structure is depicted in Fig. 3.
The active pharmaceutical ingredient naproxen sodium
(Nap) was intercalated into both MgZn-Cl and FeZn-Cl using an
anion exchange method (see ESI for details). Successful
intercalation was confirmed by XRD, IR spectroscopy, and
elemental microanalysis.
XRD patterns of the drug intercalates of MgZn-Cl are given
in Fig. 4. The reaction products show no basal reflections
characteristic of the starting material, and a shift of the 00l basal
reflections to lower angles; this corresponds to an increase in
interlayer distance, which is indicative of the incorporation of a
larger anion into the interlayer galleries (see Table 1). The
interlayer spacing increases from 8.1 Å with MgZn-Cl to 24.4 Å
for MgZn-Nap; a similar increase from 7.8 to 24.5 Å is seen for
FeZn-Nap. These expanded interlayer spacing values are in good
agreement with the literature on Nap intercalates of LDHs and
HDSs where d-spacings around 23.5 and 24.1 Å have been
reported, respectively.20,34,35 The diffraction patterns illustrate
peak broadening, indicative of stacking defects. The elemental
microanalysis results (Table 1) confirm the presence of drug,
together with some residual Cl ions in the case of MgZn-Nap and
some carbonate impurity (from dissolved CO 2 in the water used
for reaction) in the FeZn-Nap material.
The IR spectra of the drug intercalates show all the
characteristic peaks of Nap after intercalation (see Fig. S6, ESI,
for the data on MgZn-Nap), confirming successful intercalation
of intact API ions. Some of the peaks have shifted to slightly
different wavenumbers due to interactions between the guest
and host layers. The chemical integrity of the guest ions was
verified through deintercalation and analysis by NMR (data not
shown).
Fig. 3. A schematic structure of the new HDSs. Zn 2+ ions are coloured purple
and Mg2+/Fe2+ in green. The octahedral sites are located in the layers and
tetrahedral sites are situated above and below. Cl - anions shown as cyan
spheres, with water molecules (O red, H white) also visible in the interlayer
space.
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Fig. 4. XRD patterns for (a) FeZn-Nap, and (b) MgZn-Nap.


















a C and H contents were determined by quantitative combustion, and the H2O
content from TGA
In vitro drug release studies of the Nap intercalates were
undertaken in phosphate buffered saline (PBS; pH 7.4) at 37 °C;
the results are depicted in Fig. 5. FeZn-Nap displayed slower
release than MgZn-Nap. Release occurs over an extended
period of time of ca. 1280 min (21.3 h); the HDS intercalates
thus meet the pharmacopeia requirement for extended release,
which requires the API to be freed over a prolonged period of
time.36 The difference in the release rate is thought to be
related to the HDSs’ metal compositions, since it is known that
metals influence the release property from LDHs. 37,38 Release
from the HDS systems reported here is much slower from most
Nap-containing LDH systems (e.g. some Mg/Al LDH-Nap
systems where 90 % of the drug was released after 4 h). 39,40 The
range of values reported for LDH-Nap intercalates in the
literature varies widely, however: Carriazo et al. and Gu et al.
both explored Mg/Al LDH-Nap intercalates and found that 90 %
of the incorporated drug was released after 35 min and 8 h
respectively.41,42
The HDS-Nap composites were compared with literature
data on drug release from a commercially available Nap tablet,
and found to perform comparably with this (Table S8). To
further investigate the drug delivery properties of the Nap
intercalates they were formulated into tablets (MgZn-Nap-Tab
and FeZn-Nap-Tab) using commercial excipients (see ESI for
details). This required a scale-up of the initial reaction by a
factor of 200-fold (details are given in the ESI). The materials
resulting from scale-up were found to be identical to those
prepared on the small-scale. The HDS tablets were tested for
hardness, weight and content uniformity, and friability (see ESI,
Table S9) and in all cases found to meet the appropriate US
Pharmacopoeia requirements.43–45 Drug release tests
comparing tablets of FeZn-Nap and MgZn-Nap with
commercially available Naprosyn EC® (enteric-coated) tablets
were undertaken, and the results are given in Fig. 6.
Fig. 5. Drug release from the Nap-loaded HDS powders at pH 7.4. Data
from three independent experiments are shown as mean ± S.D.
Fig. 6. Nap release from tablets of FeZn-Nap and MgZn-Nap at pH 1 and
6.8. Data from three independent experiments (5 for Naprosyn-EC) are
shown as mean ± S.D.
These drug release tests were performed using
pharmacopoeia standard protocols aiming to simulate the
passage of the formulation through the human body after oral
administration. The three formulations showed virtually no
release during the first 2 h at pH 1 (mimicking the stomach). The
HDS tablets are able to protect the drug from release as
effectively as the commercial enteric coated tablet. Once the pH
was adjusted to 6.8, release from the HDS tablets proceeded in
a sustained manner (the EC tablet releases very rapidly at this
pH, in order to deliver rapid relief of symptoms). Both HDSs
display almost identical release profiles, and importantly show
sustained release over ca. 24 h at neutral pH. The HDS tablets
meet the US Pharmacopoeia requirements for
delayed/extended release dosage forms: these specify that less
than 10 % of the incorporated drug should be released in the
acidic media and the drug is freed over a prolonged duration of
time, respectively.36,46
In conclusion, two new biocompatible HDSs based on Mg/Zn
and Fe/Zn were successfully synthesised for the first time. They
comprise hexagonal platelets, and XPS data suggest that Mg 2+
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and Fe2+ occupy both octahedral and tetrahedral sites. Bioactive
guests including naproxen (Nap) have been successfully
intercalated into the new HDSs. NMR and IR spectroscopy
showed that the guest ions’ structures remained intact after
intercalation. Nap release in phosphate buffered saline (pH 7.4)
was explored, and the drug-loaded HDSs showed extended
release profiles. As a result of these promising results, HDS
synthesis was scaled up to the 100s of grams scale and tablets
were prepared with the HDS-Nap systems. The tablets
produced meet all appropriate US Pharmacopoeia
requirements both for the physical properties of the tablets and
as delayed or extended release systems. HDS-based tablet
formulations hence offer a novel platform for the design of
future dosage forms.
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